Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Minerva Neuroscie (NQ: NERV ) 2.700 -0.020 (-0.74%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Minerva Neuroscie Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates August 06, 2024 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates May 01, 2024 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia February 27, 2024 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Inc. (NASDAQ: NERV) Near the Top of Equities by Percentage Gain on 6/28 June 28, 2023 Via Investor Brand Network Minerva Neurosciences Inc. (NASDAQ: NERV) Leading the Way in Monday Trading Based on Percentage Gain May 01, 2023 Via Investor Brand Network Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates February 22, 2024 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates November 07, 2023 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates August 01, 2023 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market June 28, 2023 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates May 15, 2023 Company to host conference call today at 8:30 a.m. ET From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia May 10, 2023 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023 May 08, 2023 Management to Host Conference Call From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia May 01, 2023 FDA grants appeal and files NDA From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates March 08, 2023 Company to Host Conference Call Today at 8:30 a.m. ET From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 March 01, 2023 Management to Host Conference Call From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia December 28, 2022 From Minerva Neurosciences, Inc Via GlobeNewswire Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates November 14, 2022 EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END Via FinancialNewsMedia Topics Retirement Exposures Pension Product Safety Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates November 09, 2022 Company To Host Live Webcast Today at 8:30 a.m. ET From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022 November 02, 2022 From Minerva Neurosciences, Inc Via GlobeNewswire Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia October 17, 2022 From Minerva Neurosciences, Inc Via GlobeNewswire 5 Best Performing Micro-Cap Stocks Through the First Half of 2022 July 05, 2022 The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices Via Spotlight Growth Topics Stocks Exposures Fossil Fuels US Equities Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.